Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Active Control Study to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of P1101 + Ribavirin in Treatment-Naïve Subjects With HCV Genotype 1 Infection

NCT01587586 is registered in ClinicalTrials.gov with PharmaEssentia as lead sponsor.

NCT NCT01587586
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01587586 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Active Control Study to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of P1101 + Ribavirin in Treatment-Naïve Subjects With HCV Genotype 1 Infection
Lead sponsor
PharmaEssentia
Phase
Phase 2
Overall status
Completed
Start date
October 18, 2011
Completion date
November 22, 2016
Enrollment
107 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, chronic